Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Trump's International Pricing Proposal Being Revised To Adopt ‘Most Favored Nation’ Policy – Azar

HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.

Pricing Debate Regulation

Orphan Drug Access: One-Third Of US Coverage Decisions Involve Restrictions, Study Finds

Tufts researchers report restrictions are more common for orphan drugs indicated for diseases with higher prevalence and that are more expensive.

Reimbursement Pricing Strategies

White House Wants To Avoid Fight On Rebates, Get Quick Passage Of Senate Rx Pricing Bill

“We’re out of time for ideas," Domestic Policy Council Director Joe Grogan says. Trump administration is pushing hard to get the Senate drug pricing bill through Congress quickly and score a major victory for the President.

Pricing Debate Legislation

Rx Pricing, Rebating Should Be Back To Business As Usual In 2020, PBMs Say

Political focus of drug pricing debate has shifted away from pharmacy benefit managers, CVS Health’s Merlo suggests.

Pricing Debate Reimbursement

Drug Pricing Bill: Senate Sponsors ‘Not Backing Down’ From Inflation Rebates

Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.

Pricing Debate Medicare

US Drug Importation: Hard To See Path Forward, Former HHS Adviser Says

Former drug pricing advisor John O’Brien discusses next steps for Administration policies around importation and international reference pricing during a speech to the Academy of Managed Care Pharmacy.

Regulation Pricing Debate
See All
UsernamePublicRestriction

Register